TABLE 1.

Descriptive Statistics for Pre-Pregnancy and During Pregnancy AST and ALT

	MASLD vs. control			MASLD subgroups (based on FIB-4)
	MASLD (mean, SD) (n = 117)	Control (mean, SD) (n = 168)	p	At risk of advanced fibrosis (mean, SD) (n = 25)	Not at risk of advanced fibrosis (mean, SD) (n = 92)	p
Pre-pregnancy AST	30.7 (38.7)	22.1 (8.65)	0.02	48.0 (68.7)	26.0 (23.7)	0.127
Pre-pregnancy ALT	34.9 (57.1)	19.3 (14.6)	0.005	45.3 (43.1)	32.1 (60.2)	0.221
During-pregnancy AST	29.8 (52.9)	24.0 (9.50)	0.319	25.1 (7.07)	31.4 (61.2)	0.42
During-pregnancy ALT	26.2 (36.8)	18.1 (9.32)	0.069	22.3 (14.5)	27.5 (41.9)	0.413
Difference between during-pregnancy and pre-pregnancy AST	1.87 (59.4)	3.03 (10.3)	0.86	−13.0 (42.6)	7.00 (63.6)	0.102
Difference between during-pregnancy and pre-pregnancy ALT	−6.66 (61.6)	0.509 (11.4)	0.322	−18.3 (33.5)	−2.58 (68.6)	0.186

Abbreviations: FIB-4, Fibrosis-4 Index; MASLD, metabolic dysfunction–associated steatotic liver disease.